Cytta Name Logo.jpg
Cytta Corp's EvrCare™ achieves Realtime Live Patient Remote Monitoring from South Pole
October 17, 2019 08:00 ET | Cytta Corp.
Las Vegas, NV, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Las Vegas, Nevada, October 17th, 2019 – Cytta Corp (OTCPINK:CYCA) Cytta is pleased to announce the successful live realtime patient trials of its...
FORM_RGB_Blue.png
FORM and Polar to Bring Heart Rate to Augmented Reality Swim Goggles
September 03, 2019 00:01 ET | FORM
Vancouver, BC, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Today, FORM, the sports technology company behind the world’s first augmented reality swim goggles, and Polar, the leader in wearable sports and...
Tickets are on Sale NOW for Texas’ Authentic THE POLAR EXPRESS™ 2019 Train Ride at Texas State Railroad
July 15, 2019 06:00 ET | Texas State Railroad
PALESTINE, Texas, July 15, 2019 (GLOBE NEWSWIRE) -- Tickets are on sale now for the 2019 season of THE POLAR EXPRESS™ at Texas State Railroad.  The first POLAR EXPRESS™ of the season heads to the...
PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium
January 17, 2019 02:00 ET | PledPharma AB
Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers...
PledPharma presenterar läkemedelskandidaten PledOx® fas III-program på global cancerkonferens
January 17, 2019 02:00 ET | PledPharma AB
Stockholm, 17 januari 2019. PledPharma AB (publ) meddelar att bolagets globala fas III-program, POLAR, för PledOx® har accepterats för poster-presentation på den globala konferensen Gastrointestinal...
Delivery of study drug to the PledOx® phase III program is expected in September
August 15, 2018 02:00 ET | PledPharma AB
Stockholm, August 15, 2018. PledPharma AB (publ) announces today that delivery of PledOx® study drug for the planned phase III program is expected during September 2018. As previously announced,...
PledPharma förväntar sig leverans av studieläkemedel till fas III-programmet med PledOx® i september
August 15, 2018 02:00 ET | PledPharma AB
Stockholm, 15 augusti 2018. PledPharma AB (publ) meddelar idag att studieläkemedel till det planerade fas III-programmet med läkemedelskandidaten PledOx® förväntas kunna levereras under september...